5月22日，英派药业-B盘中上涨13.17%，报35.58港元，成交额871.6万港元。
消息面上，公司于5月13日以每股20.10港元登陆港交所，首日大涨108.26%，此后经历获利回吐股价自高点回落超15%，昨日一度下跌逾5%后今日迎来强势反弹。此外，联交所披露文件显示，公司关联方施毅于上市日以均价36.246港元增持44.76万股H股，价值约1622万港元，释放内部信心信号。基本面方面，核心产品塞纳帕利已纳入国家医保目录并于今年起正式执行医保价格，有望推动营收放量；在研管线IMP32为全球首个靶向CEACAM5的双载荷ADC，具备First-in-Class地位。需关注的是，公司仍处亏损阶段，营收尚无法覆盖高强度研发投入。
英派药业是一家专注于基于合成致死机制的精准抗癌疗法研发的商业化阶段生物技术公司，核心产品塞纳帕利已在中国获批上市，产品管线涵盖PARP1/2、PARP1、ATR、WEE1等多个靶点。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.